Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
On the Downside Radar: financing pressure. About 9.5 months of cash at its recent burn rate (Jun 30, 2026 balance sheet), an at-the-market (ATM) program filed Jul 2, 2026, and no offering in the last 90 days. Of biotech stocks in this setup with 6 to 12 months of cash, 35% sold new shares within three months and 67% were lower 60 trading days later (median -12%). How we know
$12.6MCash on Hand
9.5mo Cash Runway
Follow MTVA by emailGet an email when MTVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MTVA, unsubscribe in one click. Privacy
📣 What MTVA Says Is Next
second half of 2027 · “A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in the second half of 2027.”
Company press release, Nov 17, 2026 · SEC filing
second half of 2027 · “MetaVia is planning a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027. About MetaVia MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases.”
Company press release, Nov 17, 2026 · SEC filing
first half of 2027 · “Vanoglipel (DA-1241) in MASH: o MetaVia is currently working to schedule an End-of-Phase 2 meeting with the FDA before the end of 2026 to discuss the clinical development pathway for vanoglipel in combination with resmetirom. o Initiation of a randomized, 12-week Phase 2a non-biopsy proof-of-concept study of vanoglipel in combination with resmetirom is targeted for the first half of 2027. Third Quarter Financial and Operating Results ”
Company press release, Nov 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 17, 2026 ·
Clinical trial MetaVia said the last patient completed the final visit in its Phase 1 DA-1726 trial, with treatment extended from 16 to 24 weeks. Full Part 3A and 3B data are expected in Q1 2027, and a Phase 2 study is planned for 2H 2027. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Clinical trial Presented preclinical head-to-head data in diet-induced obese mice showing DA-1726 achieved weight loss comparable to retatrutide (41.7% vs. 43.6% at high dose, adjusted) with less food intake suppression (31.2% vs. 41.4%). DA-1726 also showed greater glucose lowering (39.2% vs. Form 8-K · SEC filing · Press release
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $4.6 million, or $0.69 per share, with R&D expenses of about $2.6 million and G&A of about $2.1 million. Highlighted positive 16-week DA-1726 Phase 1 Part 3B data, including a 68.1% placebo-adjusted liver fat reduction, and plans for a 48-week Phase 2 study in MetALD and ALD. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Clinical trial Announced additional Phase 1 Part 3B data for DA-1726 showing a 1.47 mg/dL placebo-adjusted reduction in serum uric acid after 16 weeks (p<0.001), with 15 DA-1726 and four placebo participants analyzed. Full Part 3A and 3B data expected Q1 2027. Form 8-K · SEC filing · Press release
Nov 5, 2026 ·
Clinical trial Reported positive Part 3B interim Phase 1 data for DA-1726 at 16 weeks: 68% placebo-adjusted liver fat reduction (p<0.001), 13.5% placebo-adjusted weight loss, and HbA1c down 0.24 percentage points versus placebo in non-diabetic participants. Form 8-K · SEC filing · Press release
Oct 28, 2026 ·
MetaVia announced that an abstract on Phase 1 data for DA-1726, a dual GLP-1 and glucagon receptor agonist, was accepted for an oral presentation at the Precision Liver Symposium 2026 on November 4, 2026, in Denver. The presentation covers MRI-PDFF reduction and weight loss with relative lean mass preservation. Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Leadership Appointed Sarah Browne, M.D. as Chief Medical Officer, effective October 12, 2026. She previously led pemvidutide clinical development at Altimmune through Phase 2 and an End-of-Phase 2 meeting with the FDA. The company expects Phase 1 Part 3 topline data for DA-1726 in Q4 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
MTVA holds $12.6M in cash and short-term investments (as of Jun 30, 2026) and burns about $4M/quarter from operations,
an estimated runway of 9.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:70 · High
Cash runway 10 months +30
ATM program on file since Jul 2026 +15
Shelf registration (S-3, Apr 2024) +10
Going-concern doubt in the latest 10-Q +15These conditions raise substantial doubt about our ability to continue as a going concern within one year from the issuance of these condensed consolidated financial statements.10-Q, Nov 2026
Share count 6,742,889 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MTVA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MTVA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.